<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02292966</url>
  </required_header>
  <id_info>
    <org_study_id>VHCRP1304</org_study_id>
    <nct_id>NCT02292966</nct_id>
  </id_info>
  <brief_title>Impact of HCV Treatment on Neurocognitive Functions and Brain Metabolism</brief_title>
  <acronym>HEPCOG-II</acronym>
  <official_title>Impact of HCV Eradication on Neurocognitive Functions and CNS Metabolism: a Trial of Daclatasvir, Asunaprevir and Beclabuvir for Patients With HCV Genotype 1 Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kirby Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Kirby Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine whether neurocognitive impairments experienced by&#xD;
      patients with chronic hepatitis C virus (HCV) infection can be reversed by treating HCV, with&#xD;
      a new combination of direct acting antiviral drugs (daclatasvir (DCV), asunaprevir (ASV) and&#xD;
      beclabuvir (BCV)). The study will assess the effect of HCV on the central nervous system&#xD;
      (CNS) by assessing neurocognitive function and brain injury prior to treatment, and comparing&#xD;
      it to the end of treatment, and 4, 12 and 24 weeks after treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will evaluate the effect of DCV/ASV/BCV on neurocognitive functioning and brain&#xD;
      metabolite concentrations in the frontal white matter and the basal ganglia in people with&#xD;
      chronic HCV genotype 1 infection, through a comparison of baseline and post-treatment&#xD;
      parameters.&#xD;
&#xD;
      This is an open label single arm multi-centre study. All participants will each receive&#xD;
      daclatasvir (30mg), asunaprevir (200mg) and beclabuvir (75mg) in a fixed-dose combination&#xD;
      oral tablet for twice daily administration with food.&#xD;
&#xD;
      Duration of treatment will be 12 weeks for all subjects followed by 24 weeks of observational&#xD;
      follow-up.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Anticipated">June 2016</completion_date>
  <primary_completion_date type="Anticipated">June 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Neurocognitive functioning</measure>
    <time_frame>36 weeks</time_frame>
    <description>Mean change in neurocognitive functioning (global z-score representing overall neurocognitive performance across CogState, pegboard and colours trails)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Brain metabolite concentrations</measure>
    <time_frame>36 weeks</time_frame>
    <description>Mean change in five absolute metabolite concentrations (NAA,Cho, Cr, mlo, glx)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Neurocognitive functioning</measure>
    <time_frame>12 and 24 weeks</time_frame>
    <description>Mean change in neurocognitive functioning (global z-score representing overall neurocognitive performance across CogState, pegboard and colours trails)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NAA metabolite concentration in the brain</measure>
    <time_frame>12 and 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cho metabolite concentration in the brain</measure>
    <time_frame>12 and 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cr metabolite concentration in the brain</measure>
    <time_frame>12 and 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MLO metabolite concentration in the brain</measure>
    <time_frame>12 and 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glx metabolite concentration in the brain</measure>
    <time_frame>12 and 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in neurocognitive functioning compared between subjects with and without sustained virological response (SVR)</measure>
    <time_frame>24 weeks</time_frame>
    <description>Mean change in neurocognitive functioning (global z-score representing overall neurocognitive performance across CogState, pegboard and colours trails)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in brain metabolite concentrations compared between subjects with and without sustained virological response (SVR)</measure>
    <time_frame>24 weeks</time_frame>
    <description>Mean change in absolute metabolite concentrations (NAA,Cho, Cr, mlo, glx)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Hepatitis C, Chronic</condition>
  <arm_group>
    <arm_group_label>Hepatitis C treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12 weeks of DCV/ASV/BCV therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DCV/ASV/BCV</intervention_name>
    <description>Each participant will each receive daclatasvir (30mg), asunaprevir (200mg) and beclabuvir (75mg) in a fixed-dose combination oral tablet for twice daily administration with food.</description>
    <arm_group_label>Hepatitis C treatment</arm_group_label>
    <other_name>Daclatasvir</other_name>
    <other_name>Asunaprevir</other_name>
    <other_name>Beclabuvir</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Aged 18 to 65 years&#xD;
&#xD;
          -  Chronic HCV infection as documented by positive HCV RNA at screening and positive HCV&#xD;
             RNA or anti-HCV antibody at least 6 months prior to screening&#xD;
&#xD;
          -  HCV genotype 1 - mixed subtype, indeterminate subtype or other variants of genotype 1&#xD;
             are permissible&#xD;
&#xD;
          -  Non-advanced cirrhotic defined as FibroScan ≤9.6 kPA at screening&#xD;
&#xD;
          -  HCV treatment naïve&#xD;
&#xD;
          -  Seronegative for HIV and HBsAg&#xD;
&#xD;
          -  HCV RNA level of ≥104 IU/mL (10,000 IU/mL)&#xD;
&#xD;
          -  Body Mass Index (BMI) between 18 and 35 kg/m2&#xD;
&#xD;
          -  Women of childbearing potential (WOCBP) must:&#xD;
&#xD;
             i. Have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/mL or&#xD;
             equivalent units of HCG) within 24 hours prior to the start of study drug ii. Not be&#xD;
             breastfeeding iii. Agree to follow instructions for methods of contraception for the&#xD;
             duration of the treatment and for five weeks post-treatment completion&#xD;
&#xD;
          -  Men who are sexually active with WOCBP must agree to follow instructions for methods&#xD;
             of contraception for the duration of the treatment and for 14 weeks post-treatment&#xD;
             completion&#xD;
&#xD;
          -  Sufficient proficiency in English to complete the neurocognitive assessment, as judged&#xD;
             by the investigator&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Target disease&#xD;
&#xD;
          -  Infected with HCV other than genotype 1&#xD;
&#xD;
        Medical history and concurrent diseases&#xD;
&#xD;
          -  Current hazardous consumption of alcohol, defined by an AUDIT-C score ≥4 for men and&#xD;
             ≥3 for women&#xD;
&#xD;
          -  Illicit substance use, identified by urinary drug test at screening&#xD;
&#xD;
          -  Past history of non HCV-related CNS disorder, including seizures and traumatic brain&#xD;
             injury&#xD;
&#xD;
          -  Currently on an SSRI or other neuropsychiatric therapy&#xD;
&#xD;
          -  Liver or any other organ transplant other than cornea and hair&#xD;
&#xD;
          -  Current or known history of cancer (except in situ carcinoma of the cervix or&#xD;
             adequately treated basal or squamous cell carcinoma of the skin) within 5 years prior&#xD;
             to enrolment&#xD;
&#xD;
          -  Evidence of a medical condition contributing to chronic liver disease other than HCV&#xD;
             (such, but not limited to: hemochromatosis, autoimmune hepatitis, metabolic liver&#xD;
             disease, alcohol liver disease)&#xD;
&#xD;
          -  Any gastrointestinal disease or surgical procedure that may impact the absorption of&#xD;
             study drug (subjects who have cholecystectomy are permitted to enter the study)&#xD;
&#xD;
          -  Known history of coagulopathy including, but not limited to, hemophilia&#xD;
&#xD;
          -  Uncontrolled diabetes defined as HbA1c &gt;7% at screening&#xD;
&#xD;
          -  Confirmed, uncontrolled hypertension (any screening systolic blood pressure ≥160 mmHg&#xD;
             or diastolic blood pressure ≥100 mmHg should be excluded unless discussed with the&#xD;
             study medical monitor)&#xD;
&#xD;
          -  Inability to tolerate oral medication&#xD;
&#xD;
          -  Poor venous access&#xD;
&#xD;
          -  Any other medical, psychiatric and/or social reason which, in the opinion of the&#xD;
             investigator would make the subject inappropriate for the study&#xD;
&#xD;
        Physical and Laboratory Test Findings&#xD;
&#xD;
          -  ALT ≥ 5 x ULN&#xD;
&#xD;
          -  Total Bilirubin ≥ 34 µmol/L (≥ 2 mg/dl), unless subject has documented history of&#xD;
             Gilbert's disease&#xD;
&#xD;
          -  INR ≥ 1.3&#xD;
&#xD;
          -  Albumin &lt; 3.5 g/dL (35g/L)&#xD;
&#xD;
          -  Platelets &lt; 100 x 109 cells/L&#xD;
&#xD;
          -  ANC &lt; 0.75 x 109 cells/L&#xD;
&#xD;
          -  Hemoglobin &lt; 10 g/dL (100g/L)&#xD;
&#xD;
          -  Creatinine clearance (CrCL) ≤ 50 mL/min&#xD;
&#xD;
          -  Alpha fetoprotein (AFP) &gt; 50ng/mL&#xD;
&#xD;
          -  QTcF or QTcB &gt; 580mSec&#xD;
&#xD;
          -  Positive HBsAg, HIV-1 or HIV-2 Ab&#xD;
&#xD;
        Allergies and Adverse Drug Reaction&#xD;
&#xD;
          -  History of hypersensitivity to drugs with a similar biochemical structure to DCV, ASV&#xD;
             or BCV&#xD;
&#xD;
          -  Any other criteria or know contraindication that would exclude the subject from&#xD;
             receiving DCV, ASV or BCV Prohibited treatments and/or Therapies&#xD;
&#xD;
          -  Exposure to any investigational drug or placebo within 4 weeks of study drug&#xD;
             administration&#xD;
&#xD;
          -  Refer to 5.5 for prohibited and/or restricted treatments during and post-treatment Sex&#xD;
             and reproductive status&#xD;
&#xD;
          -  Males and females who do not or are unable to meet the requirements outlined in&#xD;
             Inclusion Criterias 9 and 10&#xD;
&#xD;
        Other Exclusion Criteria&#xD;
&#xD;
          -  Prisoners or subjects who are involuntarily incarcerated&#xD;
&#xD;
          -  Subjects who are compulsorily detained for treatment of either a psychiatric or&#xD;
             physical (e.g. infection disease) illness&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gregory Dore, BSc, MBBS, FRACP, MPH, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Kirby Institute, University of New South Wales</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St Vincent's Hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westmead Hospital</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <study_first_submitted>September 25, 2014</study_first_submitted>
  <study_first_submitted_qc>November 13, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 18, 2014</study_first_posted>
  <last_update_submitted>June 2, 2016</last_update_submitted>
  <last_update_submitted_qc>June 2, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 3, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatitis C</keyword>
  <keyword>Hepatitis</keyword>
  <keyword>Asunaprevir</keyword>
  <keyword>Daclatasvir</keyword>
  <keyword>Beclabuvir</keyword>
  <keyword>Neurocognitive function</keyword>
  <keyword>Brain metabolites</keyword>
  <keyword>Direct acting antiviral therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asunaprevir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

